ANAB - アナプティスバイオ (AnaptysBio Inc.) アナプティスバイオ

 ANABのチャート


 ANABの企業情報

symbol ANAB
会社名 AnaptysBio Inc (アナプティスバイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アナティスバイオ(AnaptysBio Inc.)は米国の生物技術会社である。同社は炎症および免疫腫瘍学における満たされていない医療ニーズに焦点を当てた抗体製品候補の開発に従事する。同社は、抗体産生の自然過程をインビトロで複製するように設計された抗体発見技術プラットフォームを使用して、その製品候補を開発する。その製品パイプラインには、未治療の医療ニーズを伴う重度の炎症性障害を治療するために開発されているANB020とANB019が含まれる。ANB020製品候補は、インターロイキン-33の活性を阻害する抗体であり、重度の成人喘息および重度の成人のピーナッツアレルギーの治療に使用される。同社は、一般化した膿疱性乾癬(GPP)および掌蹠膿疱性乾癬(PPP)と呼ばれる稀な炎症性疾患の治療のために、インターロイキン36受容体を阻害する抗体ANB019製品候補の開発に従事する。   アナプティスバイオは米国のバイオ医薬品企業。臨床段階で、炎症の治療に関連する抗体医薬品の開発に従事。同社は体細胞超変異を用いる抗原結合物質を生成するプラットフォ―ムを開発、試験管内で抗体生成のプロセスを再現する。医療ニ―ズはあるが治療法がまだない炎症の分野に専念する。本社所在地はカリフォルニア州サンディエゴ。   Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.
本社所在地 10421 Pacific Center Court Suite 200 San Diego CA 92121 USA
代表者氏名 Hamza Suria ハムザスリア
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 858-362-6295
設立年月日 38657
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 60人
url www.anaptysbio.com
nasdaq_url https://www.nasdaq.com/symbol/anab
adr_tso
EBITDA EBITDA(百万ドル) -46.19900
終値(lastsale) 90.395
時価総額(marketcap) 2172774988.145
時価総額 時価総額(百万ドル) 2284.503
売上高 売上高(百万ドル) 3.00000
企業価値(EV) 企業価値(EV)(百万ドル) 228.214
当期純利益 当期純利益(百万ドル) -37.06000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AnaptysBio Inc revenues decreased from $7M to $0K. Net loss increased from $14.1M to $28.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 45% to $20.7M (expense) General and administrative - Balancing increase of 60% to $4.6M (expense).

 ANABのテクニカル分析


 ANABのニュース

   AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference  2022/08/05 20:00:00 GlobeNewswire
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 3:30 p.m. ET / 12:30 p.m. PT.
   AnaptysBio Inc. (NASDAQ: ANAB) Stock Seems Like A Good Option  2022/06/25 12:00:00 Stocks Register
AnaptysBio Inc. (NASDAQ:ANAB) shares, rose in value on Friday, 06/24/22, with the stock price up by 2.21% to the previous day’s close as strong demand from buyers drove the stock to $23.12. Actively observing the price movement in the last trading, the stock closed the session at $22.62, falling within a range of $22.18 and … AnaptysBio Inc. (NASDAQ: ANAB) Stock Seems Like A Good Option Read More »
   An Analysis Of AnaptysBio Inc.’s (ANAB) Stock Behavior  2022/06/11 14:30:00 Stocks Register
AnaptysBio Inc. (NASDAQ:ANAB) concluded the trading at $22.00 on Friday, June 10, with a fall of -3.17% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $22.72 and 5Y monthly beta was reading 0.13 with its price kept floating in the range … An Analysis Of AnaptysBio Inc.’s (ANAB) Stock Behavior Read More »
   AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference  2022/06/02 20:05:00 GlobeNewswire
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 10:00 a.m. ET / 7:00 a.m. PT.
   Short Volatility Alert: AnaptysBio, Inc.  2022/05/26 15:12:27 Benzinga
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB ) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment for ANAB has been Bearish. The signal from the volatility alert is trending Bearish . Therefore, the recommendation is to Strong Sell. The volatility alert was produced on the prior trading date, 5/25/2022, with a volatility change of +33.90%. The current volatility indicator stands at 7.237. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the … Full story available on Benzinga.com
   Short Volatility Alert: AnaptysBio, Inc.  2022/05/26 15:12:27 Benzinga
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB ) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment for ANAB has been Bearish. The signal from the volatility alert is trending Bearish . Therefore, the recommendation is to Strong Sell. The volatility alert was produced on the prior trading date, 5/25/2022, with a volatility change of +33.90%. The current volatility indicator stands at 7.237. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the … Full story available on Benzinga.com
   Looking For A Top Momentum Stock? Why AnaptysBio Inc. (NASDAQ: ANAB) Is A Great Pick  2022/05/14 18:00:00 Stocks Register
AnaptysBio Inc. (NASDAQ:ANAB) shares, rose in value on Friday, 05/13/22, with the stock price down by -0.38% to the previous day’s close as strong demand from buyers drove the stock to $21.13. Actively observing the price movement in the last trading, the stock closed the session at $21.21, falling within a range of $20.24 and … Looking For A Top Momentum Stock? Why AnaptysBio Inc. (NASDAQ: ANAB) Is A Great Pick Read More »
   AnaptysBio GAAP EPS of -$1.31 misses by $0.32, revenue of $0.97M misses by $4.08M  2022/05/04 21:41:48 Seeking Alpha
AnaptysBio press release (ANAB): Q1 GAAP EPS of -$1.31 misses by $0.32.Revenue of $0.97M (-91.4% Y/Y) misses by $4.08M.Shares -1.6% AH.Top-line data from the ongoing…
   AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update  2022/05/04 20:15:00 GlobeNewswire
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the first quarter ended March 31, 2022 and provided pipeline updates.
   AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers  2022/04/28 12:48:05 Benzinga
AnaptysBio Inc (NASDAQ: ANAB ) announced topline data from a Phase 1 trial of ANB032, an anti-BTLA agonist antibody. Topline data demonstrated favorable safety, tolerability, and rapid and sustained pharmacokinetics and pharmacodynamic profile, supporting the advancement of ANB032 into subsequent patient trials. ANB032 was generally well-tolerated, and no dose-limiting toxicities were observed. The Company said that ANB032 demonstrated rapid … Full story available on Benzinga.com
   3CLogic Achieves ISO/IEC 27001:2013 Certification  2022/03/30 07:07:00 Kwhen Finance
   AnaptysBio cut to neutral at Guggenheim on future of pipeline  2022/03/22 13:25:51 Seeking Alpha
Guggenheim has downgraded AnaptysBio (ANAB) to neutral from buy and removed its price target.
   The Daily Biotech Pulse: Merck''s Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout  2022/03/22 12:31:49 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck''s Keytruda Monotherapy Approved For A Type Of Endometrial Cancer Merck & Co., Inc. (NYSE: MRK ) said the U.S. Food and Drug Administration has approved its cancer immunotherapy as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, as determined by a FDA-approved test. These patients should have had disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. Merck shares were up 0.18% to $79.20 in premarket trading. Pfizer Announces Deal To Supply 4M Oral COVID-19 Treatments To Low- And Middle-Income Countries Pfizer, Inc. (NYSE: PFE ) announced an agreement with UNICEF to supply up to 4 million treatment courses of its COVID-19 oral treatment Paxlovid to 95 low- and middle-income countries pending authorization or approval.
   AnaptysBio names interim CEO as Hamza Suria steps down  2022/03/21 20:29:54 Seeking Alpha
AnaptysBio (ANAB) said it has appointed Daniel Faga as its interim President and CEO, effective immediately. The transition comes as Hamza Suria stepped down from his role…
   AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne  2022/03/15 12:07:00 Benzinga
AnaptysBio Inc''s (NASDAQ: ANAB ) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints. Imsidolimab was generally safe, well-tolerated, and no imsidolimab-related serious or severe adverse events were reported. Based on the results, AnaptysBio will discontinue imsidolimab clinical development in acne. The primary endpoint of facial inflammatory lesion … Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アナプティスバイオ ANAB AnaptysBio Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)